David A. Siegel Allakos Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Allakos Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 33,100 shares of ALLK stock, worth $9,599. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,100
Previous 62,500
47.04%
Holding current value
$9,599
Previous $40,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ALLK
# of Institutions
79Shares Held
68.8MCall Options Held
20.9KPut Options Held
0-
Bvf Inc San Francisco, CA16.6MShares$4.8 Million0.75% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$1.78 Million0.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.7MShares$1.65 Million0.3% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.63MShares$1.05 Million1.7% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.59MShares$1.04 Million0.01% of portfolio
About Allakos Inc.
- Ticker ALLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,726,096
- Market Cap $24.6M
- Description
- Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...